Viiv combination just as effective every two months, data shows

HIV specialist ViiV Healthcare has presented positive 48-week data showing that every-two-month regimen of an investigational long-acting, injectable two-drug regimen has similar efficacy to once-monthly dosing.

The company, which is majority-owned by UK pharma major GlaxoSmithKline (LSE: GSK), presented the data from its global phase III ATLAS-2M study of its own cabotegravir and Janssen’s rilpivirine, for the treatment of HIV.

"Study participants overwhelmingly preferred both the monthly and every-two-month long-acting regimens, over oral treatment"This study met its primary endpoint at Week 48, showing that the antiviral activity and safety of long-acting cabotegravir and rilpivirine administered every eight weeks was non-inferior when compared to its administration every four weeks.